Convenience and price improve; magnitude does not match the injectable head-to-head.
Pivotal readouts for oral GLP-1 agents report mean weight reduction below the roughly 20% seen with injectable tirzepatide in SURMOUNT-1 and SURMOUNT-5. The gap is meaningful rather than marginal.
For a patient the trade is explicit: a daily tablet at a lower price with a smaller expected effect, against a weekly injection at a higher price with a larger one. Neither answer is universally right.
Where orals change the calculation most is for patients who will not inject at all. A smaller effect actually taken beats a larger one declined.
Watch for marketing that compares an oral agent's best-case figure against an injectable's average. The analyses are not interchangeable and the populations differ.
Sources
- ATTAIN-1 and related oral GLP-1 programme readouts, 2026
- SURMOUNT-1, NCT04184622 — source
Dated 2026-05-01. If this item is out of date or wrong, tell us through contact and the change is logged in corrections.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.